Yield Growth (BOSS.C) has decided not to proceed with the previously announced investment into Absolem Health, instead advancing with their own subsidiary, Flourish Mushroom Labs, which has completed its acquisition of edible mushroom formulas.
The global edible mushrooms market is expected to grow at a compound annual growth rate of 7.95% and could reach USD$62B by 2023, according to Research and Markets.
We covered Absolem’s entry into the psychedelic/fungal space with our profile on Cambridge House’s XFuture conference which featured a number of soon-to-be public psychedelic treatment companies.
Penny White, CEO of Yield Growth, previously said her company intended to “use our alliance with Absolem as a launch pad to create assets for legal psychedelic medicine.”
The formulations include soups, teas, hot cocoa, elixirs and truffles. Flourish has engaged the developers to create additional products to add to the base catalogue and commercialize the formulas, going to market first with mushroom based soups and coffees.
Days after the article’s release, Yield put out a puzzling release stating their subsidiary, Flourish, was in talks to purchase a mushroom cookbook featuring nine recipes for teas, soups and self-care products despite the announced investment into Absolem, a company with its own line of mushroom-infused edibles.
In retrospect, we should’ve seen this coming, but shroomstocks.ca is still working on prying our third-eye open. Any readers with spare Turkey Tail can send it to our office on W. Georgia Street!
Flourish purchased their formulations for 120,000 shares of Yield Growth priced at $0.25 per share.
A fungi-enthusiast’s survivor guide
Turkey tail, lion’s mane, reishi, psilocybin…I just want some dang mushrooms, amirite? Here’s what you need to know the next time you’re in the checkout line trying to figure out which does what.
Cordyceps: A prominent component of traditional Chinese medicine, cordyceps are not actually mushrooms at all. The fungus is closely related to mushrooms and parasitizes larval hosts, growing out of their bodies and consuming them.
A 1998 study out of the Beijing Medical University Sports Institute aimed to validate longstanding claims of the fungi’s restorative properties. The double blind trial found mice given cordyceps “were able to swim significantly longer than the control groups,” showing a 73% increase in endurance.
Lion’s mane: This mushroom is touted as a countermand to anxiety and diminishing brain function by reducing inflammation. Amycenone, a compound within lion’s mane, has been found to have anti-depressive properties by the Chiba University Center in Japan.
These findings suggest that amycenone has antidepressant effects in LPS-induced inflammation model of depression. Therefore, amycenone could represent a potential supplement to prevent inflammation-related depression.
Reishi: With annual sales exceeding USD$2B, the reishi mushroom is the most famous of all medicinal mushrooms, according to Martin Powell’s “Medicinal Mushrooms, A Clinical Guide.”
G. lucidum shows “exceptionally high tyrosinase inhibition,” according to Powell, which may play a role in the reduction of Parkinson’s Disease.
I drink a reishi tea before bed and have felt much more refreshed since beginning my reishi regimen, though that’s purely anecdotal and hardly scientific.
Turkey tail: Known for its plumage-like shape, this mushroom may stimulate the human immune system and is actually approved in Japan as a supplementary treatment to conventional therapies in the treatment of cancer.
The mushroom may help repair immune cell damage caused by chemotherapy, and its immune-boosting properties making it a welcome addition to any cancer treatment.
A randomized clinical trial in Japan done between 1978 and 1981 included 751 patients who had surgery for gastric cancer. After surgery, patients received chemotherapy with or without PSK. On average, the patients who received chemotherapy and PSK lived longer than those who received chemotherapy alone.
Mushrooms, prostates and you
Earlier this week, Tohoku University in Japan suggested a link between eating plain-old mushrooms and a lower risk of prostate cancer.
The study tracked the outcomes of more than 36,000 Japanese men over a decade to investigate the health benefits of eating mushrooms.
In 2018, prostate cancer was the second most commonly diagnosed form of cancer in men after lung cancer, accounting for 14.5% of all diagnoses excluding melanoma.
“Test-tube studies and studies conducted on living organisms have shown that mushrooms have the potential to prevent prostate cancer,” said Shu Zhang, an assistant professor of epidemiology in the Department of Health Informatics and Public Health at Tohoku University School of Public Health, Graduate School of Medicine in Japan, and lead author of the study.
The study found those who consumed mushrooms once or twice a week had an 8% lower risk of getting prostate cancer compared to those who ate mushrooms less than once per week. Participants who consumed mushrooms three or more times per week at a whoppin’ 17% lower risk than the lowest percentile group.
Besides being a rich-source of vitamins and antioxidants, contains L-ergothioneine which is believed to mitigate oxidative stress, a cellular imbalance which can lead to chronic inflammation, a known cause of cancer, according to Zhang.
“Considering the average American consumes less than 5 grams of mushrooms per day, which is lower than that consumed by the participants in this study (7.6 g/day) one would expect that even a small increase in mushroom consumption to offer potential health benefits,” Zhang said.
Full disclosure: Yield Growth is an equity.guru marketing client.